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Abstract
Background and Aims: Unnatural self-organizing biomimetic polymers (foldamers) emerged as promising materials for
biomolecule recognition and inhibition. Our goal was to construct multivalent foldamer-dendrimer conjugates which wrap
the synaptotoxic b-amyloid (Ab) oligomers with high affinity through their helical foldamer tentacles. Oligomeric Ab species
play pivotal role in Alzheimer’s disease, therefore recognition and direct inhibition of this undruggable target is a great
current challenge.
Methods and Results: Short helical b-peptide foldamers with designed secondary structures and side chain chemistry
patterns were applied as potential recognition segments and their binding to the target was tested with NMR methods
(saturation transfer difference and transferred-nuclear Overhauser effect). Helices exhibiting binding in the mM region were
coupled to a tetravalent G0-PAMAM dendrimer. In vitro biophysical (isothermal titration calorimetry, dynamic light
scattering, transmission electron microscopy and size-exclusion chromatography) and biochemical tests (ELISA and dot blot)
indicated the tight binding between the foldamer conjugates and the Ab oligomers. Moreover, a selective low nM
interaction with the low molecular weight fraction of the Ab oligomers was found. Ex vivo electrophysiological experiments
revealed that the new material rescues the long-term potentiation from the toxic Ab oligomers in mouse hippocampal slices
at submicromolar concentration.
Conclusions: The combination of the foldamer methodology, the fragment-based approach and the multivalent design
offers a pathway to unnatural protein mimetics that are capable of specific molecular recognition, and has already resulted
in an inhibitor for an extremely difficult target.
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Introduction
Unnatural self-organizing biomimetic polymers (foldamers)
emerged as promising materials for protein recognition and
inhibition [1–3]. Their tunable molecular frameworks can offer
interaction surfaces to address receptors, protein-protein interac-
tions and enzymes. Such targets are the somatostatin [4] and the
transmembrane region of the integrin aIib [5] receptors, the p53-
hDM2 [2,6–9] and BH3-Bcl-xL [10–13] interactions, the gp41
virus cell infusion protein assembly, [14–17] and the c-secretase
enzyme [18]. Foldamers may have the potential to improve on
monoclonal antibodies and related protein therapeutics [19]
thanks to their considerably smaller size, their bottom-up designed
modular chemical structures, their resistance to hydrolysis and
their tunable pharmacokinetic properties [20–23]. Nonetheless, it
is still a major challenge to construct foldamers with a contiguous
recognition surface, [24–28] or long sequences with broadly
distributed recognition contacts [17].
In this work, foldameric recognition elements were utilized to
capture the b-amyloid (Ab) oligomer aggregates. These Ab species
correlate with the severity of Alzheimer’s disease (AD) [29–32].
Soluble Ab oligomers may contribute to learning and memory
deficits in AD by inhibiting NMDA-receptor-dependent long-term
potentiation (LTP), a cellular substrate of learning and memo-
ry.[33–35] Ab oligomers [33,36,37] are difficult targets for various
reasons: (i) their high-resolution structure is not known, (ii) they
exist as transient mixtures of various species, (iii) they have a high
disorder content, and (iv) the potential binding regions are exposed
to the solvent. The disadvantageous properties call for an antibody
approach, and a quest is currently under way for therapeutically
effective neutralizing antibodies against toxic Ab aggregates.[38–
42] Engineered proteins have also been shown to interact tightly
with various Ab species: affibody Zab3, [43,44] miniature protein
TJ10, [45] single chain variable fragments [46,47] and green
fluorescent protein derivatives [48,49].
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Here, we discuss foldamer-based protein mimetics which were
designed by following the principles of multivalent biomolecule-
recognizing ligands [50–60]. Divalent size-selective chemical
probes for Ab oligomers [61,62] and a tetravalent peptide-
dendrimer conjugate Ab aggregation inhibitor [63] have been
reported earlier. In this work, foldamer-dendrimer conjugates
were constructed with ordered recognition segments (helical
foldamers) and disordered linker regions (G0-PAMAM dendri-
mer). This arrangement afforded wrapping of the Ab(1–42)
oligomers through the repeating binding sites displayed over the
oligomeric surface. The new material rescues the long-term
potentiation (LTP) from the toxic Ab oligomers in ex vivo mouse
hippocampal slices.
Results
Design of the foldamer segments
Results on peptides interacting with Ab [64–70] and the
structural analysis of peptide – Ab interactions [71] suggested that
the Ab(16–22) (KLVFFAE) segment is likely to play roles in
formation of the binding patch over the surface of the Ab species.
This region offers hydrophobic interactions in the core and
potential salt-bridges through the flanking K16 and E22 residues.
We adopted this working hypothesis for the design of the
foldameric helices. Short helical b-peptide foldamers with diverse
secondary structure, zwitterionic side chain pattern and hydro-
phobic cyclic-residues were applied as potential recognition
segments in the foldamer-dendrimer conjugate ligands (Figure 1).
The short foldamers can direct 3–4 side chains toward a flat
protein surface, and in general, they can exhibit only weak
(KD.10 mM) binding, which can be detected by NMR methods.
The foldamer helices were synthesized by using b3-amino acids
with proteinogenic side-chains, various diastereomers of alicyclic
b-amino acids with 6- or 5- membered side chains and natural a-
amino acids. The helical folds were structurally induced by using
the recently published principle of backbone stereochemical
patterning, so that the small-sized library contained pure b-
peptidic H14, H12, H10/12 and H14/16 helices and the a, b-
peptidic H9-12 helix type [72].
Testing the foldamer – Ab interactions by NMR
Saturation transfer difference (STD) NMR was employed to
screen the weak foldamer – Ab(1–42) oligomer interactions. For all
the tests in this work, the Ab oligomer samples were prepared by
using the Ser26 depsipeptide aproach, [73] which furnishes the
native sequence at pH 7.4 (see details in the Materials and
Methods). Compound 1 exhibited well-detectable signals in the
whole 1H-NMR spectrum (Figure 2). This was confirmed via
transferred-nuclear Overhauser effect (tr-NOE) spectroscopy
(Figure S1). The structure refinement indicated that this foldamer
adopts an H14 helix in aqueous buffer. Thus, the b3-homo-Arg
and b3-homo-Asp side chains are in i – i+3 juxtaposition. The
long-range NOE interactions characteristic of the H14 helix could
also be found in the tr-NOESY spectrum recorded in the presence
of the target, which strongly suggested that the binding confor-
mation of 1 is H14 helix. The structurally related 2 and 4
displayed weak saturation transfer effects only. No signal was
observed for 3 supporting the importance of the helical
conformation and the zwitterionic pharmacophore in the binding.
To test the necessity of the proximity of the ion pair for binding, 5
was measured where the ionizable side chains point to opposite
directions. For 5, no interaction was found in STD. The virtually
featureless 6 was utilized as a negative control and it did not
exhibit an STD effect.
Design and synthesis of the foldamer-dendrimer
conjugates
It is very likely that Ab oligomers have a periodic structure, and
binding patches for 1 are therefore displayed repetitively.
Accordingly, it was expected that the tethering of 1 to a suitable
multiple-armed template would lead to a tightly binding multiva-
lent ligand. For this purpose, a generation zero poly-amido-amine
(G0-PAMAM) dendrimer was employed. The C-terminus of 1 was
functionalized with a Gly-Gly-Cys linker and the resulting
sequence was ligated to the four-armed tetra-maleimidopropion-
lyl-PAMAM derivative. The foldamer-G0-PAMAM conjugate 7 is
depicted in Figure 3 (for the chemical structure see Figure S2).
The foldamer segment exhibited the long-range NOE interactions
characteristic of the H14 helix, whereas the dendrimer moiety
remained unstructured (Figure 4). The effects of multivalency on
the binding properties were studied with the help of 8, a divalent
conjugate obtained by ligating 1 to a bis-maleimido-butane linker
(Figure S2). To gain an initial insight into the structure-affinity
relationship features of the tetravalent ligands, 4, 5 and 6 were also
coupled to the G0-PAMAM template, leading to compounds 9, 10
and 11, respectively.
Nanomolar and stoichiometric interaction between 7 and
the Ab oligomers (ITC and DLS)
Binding of 7 to the Ab oligomers was monitored by means of
isothermal titration calorimetry (ITC). Since precipitation was
observed in the ITC cell, dynamic light scattering (DLS)
measurements were carried out in parallel (Figure 5A). The
titrations were run at 288 K in order to improve the signal to noise
ratio, and just above the precipitation limit as the ITC method is
sensitive to the thermal noise caused by the stirring of large
particles. After correction for the heat of ligand dilution, the
sample containing 72 mM Ab in the titration cell exhibited a two-
stage enthalpogram (Figures 5A and S3). The first binding step
had KD = 6.961.4 nM, DHb = 7.2460.05 kcal mol
21 and
N = 0.04160.00089, whereas the lower affinity interaction was
characterized by KD’ = 281.1638.7 nM, DHb’ = 2.5860.02 kcal
mol21 and N’ = 0.1860.002. These values strongly supported
tight binding between the Ab oligomer species and 7. DLS data
(Figure 5A) revealed that the first binding event did not affect the
average particle size, while the precipitation started just before the
equivalence point of the second stage.
Effects of multivalency on the binding affinities as
detected by ITC and ELISA
The ITC titration with 8 resulted in a single-stage enthalpogram
(Figure 5B, KD = 721.46120.1 nM, DHb = 1.160.12 kcal mol
21
and N = 0.5360.003) and the parameters correlated well with
those measured for 7 in the second stage. The rather low
endothermic DHb for 1 made fitting difficult, but the stoichiometry
clearly increased to ,1:1 (N = 0.9760.05) and KD increased
above 2 mM. Neither 8 nor 1 led to concentration-dependent
precipitation.
Biotin-labeled 1 was prepared by elongating the foldamer
segment with a biotinyl-aminohexanoyl-Gly-Gly moiety and these
derivatives were coupled to G0-PAMAM which furnished biotin-
labeled 7. Biotinyl-8 was also prepared. All the labeled ligands
were attached to the streptavidin functionalized microplates with
a coverage of 5 pmoles per well. The ELISA datasets (Figure 6A)
revealed that biotinyl-7 successfully captured Ab oligomer species
at nanomolar affinity, even on the solid support. Because of the
potential sterical shielding of the recognition segments over the
surface, the ITC affinities cannot be directly compared to the
Foldamers Neutralizing Ab Oligomers
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ELISA results. The IC50 values for biotinyl-8 and -1 exhibited the
same increasing trend as observed for the apparent KD-s in the
ITC titrations.
These results demonstrated the effects of multivalency and
strongly suggested that low nanomolar binding and affinity
precipitation were possible only with 7 in this set. Divalent 8 still
exhibited submicromolar affinity, but it was not able to initiate
ligand-induced precipitation. The stoichiometric (1:1) binding
observed for 1 indicated that one binding patch is formed per an
Ab chain, and these interaction sites are all available on the
surface. ITC titration with monomeric Ab sample did not exhibit
submicromolar binding suggesting that a certain aggregation level
is necessary for the tight and stoichiometric binding of 7.
Initial structure-affinity relationship tests on the
foldamer-dendrimer conjugates
ITC measurements with 9, 10 and 11 did not reveal any tight
binding to the Ab oligomer species (Figure S4). This phenomenon
was tested also in a capture ELISA. Biotin-labeled 4 and 5 were
prepared as described and ligation to G0-PAMAM yielded biotin-
labeled 9 and 10, respectively. ELISA measurements confirmed
the ITC findings (Figure 6B). The high-affinity interaction
tolerated neither the removal of the ionic side-chains (9) nor the
changing of the position of the b3-hAsp residue (10), which
supported the selective nature of the interaction. Interestingly, the
ELISA curve recorded with fibrillar Ab and biotinyl-7 also
indicated decreased affinity suggesting the size-selective nature of
the nM interaction (Figure 6C).
Selective low nM interaction of 7 with the LMW fraction
of Ab oligomers
ITC measurement for 7 indicated fractional stoichiometry for
the low nM binding, which pointed to that the high affinity
interaction involves only a fraction of the oligomeric Ab sample.
To localize the strongly binding fraction in the mixture, size
exclusion chromatographic (SEC) separation was carried out and
the resulting Ab oligomer fractions were tested with 7 in
concentration-dependent dot blot experiments. Two dominant
peaks were found in the SEC chromatogram corresponding to the
high molecular weight (HMW) and low molecular weight (LMW)
components (Figure 7). The LMW fraction displayed saturation of
binding in the low nanomolar region, whereas HMW species were
stained with just below micromolar affinity. In control experi-
ments, specific and/or preferential binding of Ab by the
membrane itself were ruled out. These findings were in line with
the ITC and ELISA results. It could be concluded that 7
preferentially bound to the LMW fraction at low nM concentra-
tion and also interacted with the HMW fraction at sub-mM level.
Figure 1. Design principles of the foldamer-dendrimer conjugates. Foldamers based on unnatural b-amino acid building blocks (R:
proteinogenic side chains) fold into short helices (A). Foldamers exhibiting weak binding to the target can be identified by using NMR spectroscopic
methods (B). Chemoselective ligation of the synthetic recognition segments with flexible linkers yields amplified affinity to the target (C). Blue
spheres are schematic representation of the Ab oligomers.
doi:10.1371/journal.pone.0039485.g001
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Effects of the binding on the particle size and on the
secondary structure of the oligomeric Ab
The concentration-dependent increase of the particle size
described above raised the question if this phenomenon was
linked to an accelerated fibrillization or to any form of
conformational remodeling of the Ab oligomers. The TEM
(transmission electron microscopy) images (Figure 8), revealed that
7 caused association of the spherical oligomers a few nm in size
into bundles of aggregates in the mm range. The shape of the
aggregates was unequivocally different from that of the mature
fibrils.
The electronic circular dichroism (ECD) results indicated that
the pure Ab oligomer solution contained a mixture of b-sheet and
random coil conformations (Figure 9A). The data on 7 were in
agreement with its largely helical structure, also found via NMR.
Mixing 0.25 equivalents of 7 with 36 mM Ab solution did not lead
to an immediate increase in the b-sheet content. As the
conformation of the ligand concerns, the intensity of the negative
lobe decreased significantly at around 220 nm, but a significant
change was not observed below 210 nm. This suggested that 7
retained its helical conformation content since minor geometry
changes can alter the band intensities for short b-peptidic
foldamers significantly, while disordering would have caused a blue
shift. This was in accord with the NMR results obtained for the
recognition segment 1. The secondary structure was probed also
with ThT binding experiments (Figure 9B). Pure Ab oligomers
bound ThT at a certain level. This was in accord with the staining
with antibody OC; both are capable of recognizing the fibrillar (or
protofibrillar) oligomers. Compound 7 had no significant effect on
the ThT binding. The biophysical characterization by using TEM,
ECD and ThT binding confirmed that conformational remodeling
did not occur upon binding: disaggregation of the oligomers into
random coil structure was not observed and the particle size
increase was due to the non-covalent cross-linking with 7. The
latter process is similar to affinity precipitation.
The higher affinity of 7 toward the LMW oligomer fraction and
the lack of size-selectivity for the dimeric 8 suggested that the
LMW fraction, possibly binding more than two tentacles of 7,
exhibits a decreased tendency to the affinity precipitation. This
hypothesis was tested via SEC analysis (Figure 10A). Mixtures of
50 mM Ab oligomers with 7 in 0.25 and 1.0 equivalents were
injected on the SEC column after filtration. At 0.25 equivalents,
the HMW fraction fully precipitated and disappeared from the
SEC chromatogram, whereas the LMW fraction remained intact.
At 1.0 equivalents, the HMW fraction again disappeared and
a partial decrease was observed for the LMW fraction. We
concluded that the affinity precipitation occurs for the HMW
component, but the LMW fraction is also affected at higher ligand
concentrations. The control SEC chromatogram of 7 was
recorded and it exhibited anomalously longer retention time due
to its compact geometry. Thus it was possible to test if the LMW
fraction co-elutes with 7. LC-MS was run on the LMW fraction
taken at 19 min and both Ab and 7 were identified in the
chromatogram in a comparable amount (Figure 10B). The HMW
precipitate was also tested for the presence of 7 with LC-MS, and
the result confirmed the heterocomplex nature of the product
(Figure 10C).
The extent of precipitation was also tested at an Ab oligomer
concentration of 1 mM. The Ab oligomer sample was mixed with
0, 0.2, 0.5 and 1.0 equivalents of 7, centrifuged at 150006 g for
3 h and the supernatant was tested for residual Ab concentration
by using a standard ELISA (Figure 11). This measurement
displayed no significant loss of soluble material at 1 mM, which
facilitates biological experiments at this concentration without
titrating Ab out of the solvent upon adding 7.
Foldamer-dendrimer conjugate 7 rescues LTP ex vivo
We investigated whether 7 could protect against the synaptic
plasticity damage caused by Ab(1–42) oligomers by using
a hippocampus slice LTP model. LTP, a correlate of learning
and memory has been repeatedly shown to be impaired by Ab(1–
42) oligomers. As negative control, substance 11 was applied. The
experimenters were blind to the compounds tested.
Untreated slices exhibited a robust potentiation (17565%,
n = 7, Figure 12A), and LTP was reduced by the Ab(1–42)
oligomer at 720 nM (12865%, n = 7, p = 0.003). The application
of Ab(1–42) oligomers and 7 (950 nM) together resulted in normal
LTP (19565%, n = 6, Figure 12B), but the control with Gly7
tentacles (11) did not lead to rescue from the toxic effect (13063%,
n = 6, p#0.001 vs. 11 alone). Importantly, neither 7 nor 11 alone
exerted any effect on LTP (184616%, n = 6 and 200614%, n = 6,
respectively) which indicates that the protective effect is Ab-
dependent (Figure 12C). These observations indicate the signifi-
cant protective effect of 7 (Figure 12D). To test the effects of
Figure 2. Screening for the foldameric recognition segments. Informative regions of the STD spectra (A–F for 1–6, respectively) in the
presence of Ab(1–42) oligomers. The spectra were recorded in 20 mM phosphate buffer at pH 7.4, the total concentration of the Ab(1–42) was
72 mM, and the ligands were applied at 2 mM. The secondary structure type is indicated to the right of the structures. ‘H’ stands for helix, and the
numbers show the size of the H-bonded pseudocycles stabilizing the helices.
doi:10.1371/journal.pone.0039485.g002
Figure 3. Foldamer-tetra-maleimidopropionyl-G0-PAMAM
(TMP) and -bis-maleimido-butane (BMP) conjugates studied.
ACHC stands for trans-2-aminocyclohexanecarboxylic acid. In the
structure of 7, the H14 helical conformation adopted by the foldamer
segments in water is indicated (red), whereas the flexible linker is in an
arbitrary conformation (green).
doi:10.1371/journal.pone.0039485.g003
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valency, LTP experiments were repeated with 8 under the same
conditions. No rescue from the toxic Ab oligomers was observed
for 8 (Figure 12E).
Discussion
Foldameric helices were designed based on the assumption that
an organized hydrophobic surface flanked by zwitterionic side
chains may lead to ligands binding to the Ab oligomeric species.
The NMR screening carried out on foldamers with various
secondary structures resulted in that a H14 helix built with 2-
aminocyclohexanecarboxylic acid (ACHC) residues and ionizable
b3-amino acids (1) is indeed capable of weak binding to the target.
The initial structure affinity relationship study suggested that the
pharmacophore is well defined; changing arrangement/nature of
the hydrophobic side-chains, removal of the zwitterionic feature
and the distance between the charged side-chains abolish binding.
In order to amplify affinity, a tetravalent foldamer-dendrimer
conjugate (7) was designed and synthesized. Various methods
revealed that 7 captures Ab oligomers stoichiometrically with
submicromolar affinity, and a selective low nanomolar interaction
with the LMW oligomer fraction was observed. Due to the
multivalent nature of the ligand, affinity precipitation occurred at
higher target concentrations. For the divalent 8, neither the low
nM binding affinity toward the LMW Ab oligomers nor the
affinity precipitation occurred. Moreover, the reduced ligand-
induced precipitation tendency for the LMW fraction strongly
suggests that the low nM binding requires more than two or
possibly all the recognition segments of 7. The stoichiometric
binding of the ligands and the effects of multivalency may carry
important information on the solution structure of the Ab
oligomers. This may open up new directions in the structural
analysis of the Ab oligomers.
Designed Ab binding proteins [43–49] have been shown to
capture monomeric Ab as demonstrated by X-ray and SPR
studies (carried out on immobilized monomeric Ab). This type of
Figure 4. NMR assignments and long-range NOE interactions. Data are displayed for the foldamer segments and the maleimide
diastereomers for 7, 8, 9 and 10 in panels A, B, C and D, respectively. Crosspeaks in the overlaid TOCSY (red) and ROESY (blue) spectra prove the H14
structure of the foldamers. The long-range NOEs supporting the helical conformation were observed in aqueous medium. The addition of the thiol
group to the maleimido moiety generates an additional stereogenic center. The NMR resonances of the Cys-maleimide linker region are split and
their integrals indicate that the addition is not stereoselective; R and S configurations can be found in equimolar ratio (S and R maleimide
diastereomers are signed with black and blue, respectively). Since this undetermined configuration moiety is in the flexible part of the molecule, the
effect of the chiral center does not propagate further toward either the foldamer part or the PAMAM template.
doi:10.1371/journal.pone.0039485.g004
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interaction arrested the aggregation process and the formation of
the toxic species could be avoided. The multivalent structures
containing the KLVFF segment [61–63] target the LMW
oligomers through assumed incorporation into the b-sheet
structure. The selective interaction with LMW oligomers have
been demonstrated for dimeric structures [62]. The aggregation
process could also be inhibited this way, but protecting effects
against the toxic Ab oligomers have not been described.
In ex vivo measurements, 7 provided rescue from the LTP
inhibiting effect of the Ab oligomers at submicromolar concentra-
tions in an Ab-dependent manner, whereas 8 was not active. The
protective effect was immediate on the time scale of the LTP
measurements; it did not require preincubation of the Ab oligomer
samples with the ligand. As concerns the mechanism of action, our
results do not support any conformational remodeling in the Ab
oligomer mixture at the ligand concentration applied (e.g., shifting
the equilibrium toward monomeric Ab). Many protective agent
cited above have been shown to act as aggregation inhibitor, but
the mechanism is different in this case. The tight and stoichio-
metric binding of 7 to the target may efficiently block the toxic
surface of the Ab oligomers which leads to the LTP rescue.
Methods to protect synaptic plasticity from the neurotoxic
species have been described in the literature. These interventions
improve specific synaptic processes of LTP damaged by Ab via
CaMKII activation and subsequent AMPA receptor phosphory-
lation [74] or reduction of mitochondrial superoxide formation
[75]. The corresponding compounds act on general routes without
intercepting and neutralizing Ab, whereas anti-Ab antibodies have
also been shown to rescue hippocampal LTP in vivo [76]. We
followed the latter strategy with a synthetic protein mimetic.
In general, the described approach offers a pathway to
unnatural molecules that are capable of specific molecular
recognition, and has already resulted in an inhibitor for an
extremely difficult target. Although this new class of bioactive
materials has potential advantages over certain protein therapeu-
tics, further studies will be necessary to test its therapeutic and/or
diagnostic utility with a special focus on the ability of crossing the
blood-brain-barrier.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to the ethics
statement and approval of the National Ethics Committee for
Animal Experimentation and of the Ethics Committee of
University of Szeged (approval no.: XXVII./03405/2008). The
animals were kept and the experiments were conducted in
conformity with Council Directive 86/609/EEC and with the
Hungarian Act of Animal Care and Experimentation (1998,
XXVIII).
Preparation of the toxic Ab(1–42) oligomer samples
Preparation of the synaptotoxic Ab(1–42) oligomers: In this
work, a depsipeptide derivative of Ab(1–42) was utilized, [73]
which was converted to the native sequence by applying
physiological pH. At pH 7.4, oligomers are spontaneously formed
without the application of any detergent or residual organic
solvent in the final sample. The Ser26 depsipeptide iso-Ab(1–42)
was synthesized and purified as reported earlier [73]. The
standardized protocol for the preparation of the toxic oligomer
samples was as follows. The lyophilized iso-Ab(1–42) was treated
with HFIP for 24 h, after which the organic solvent was
thoroughly removed in vacuo. The resulting material was dissolved
in MilliQ water to a concentration of 1 mM, sonicated for 10 min
and diluted into PBS buffer (pH 7.4) to nominal concentration of
100 mM. The sample was incubated at 37uC for 24 h. The peptide
content of the final sample was determined by amino acid analysis
to be 72%. This oligomeric stock solution was either applied
directly or diluted to the required concentration with PBS prior to
use. The aggregation grade was monitored with various
techniques; the toxicity was proved in ex vivo LTP experiments.
Characterization of the Ab(1–42) oligomer samples
Conformation-specific antibodies. Staining with the con-
formation-specific antibody A11 [77,78] gives negative reaction,
whereas the positive reaction with antibody OC [79] indicated the
protofibrillar nature of the oligomers.
SEC. The size exclusion chromatogram revealed two peaks
(Figures 7 and 10) in the size ranges of 8–22 kDa and 123–
Figure 5. Tight binding between ligand 7 and the Ab oligomers as determined by ITC. (A) ITC enthalpogram for the titration of the 72 mM
Ab oligomer with 7 up to 0.55 equivalents (triangles, left scale). Data was fitted with the two independent site model (black). The corresponding z-
average diameters (squares) measured by using DLS are displayed on the right vertical scale. (B) ITC enthalpograms obtained for 1 (diamonds) and 8
(circles) at 72 mM Ab oligomer concentration.
doi:10.1371/journal.pone.0039485.g005
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908 kDa, which correspond to the low molecular weight (LMW)
and the high molecular weight (HMW) oligomer populations.
SDS-PAGE and Western Blot. We also examined the size
distribution of the oligomers by means of conventional denaturing
SDS-PAGE (Figure S5), applying antibodies BAM10 and OC for
staining. The fresh sample contained mainly monomers and LMW
oligomers, whereas after 24 h, HMW oligomers were present
besides the LMW fraction and the monomer population was
undetectable. Staining with antibody OC confirmed the fibrillar
(protofibrillar) nature of the oligomers.
ThT binding. The relative fluorescence values were moni-
tored up to 24 h, and the results indicate that Ab oligomers bind
ThT at a certain level (Figure 9B). This is in accord with the
staining with antibody OC, both capable of recognizing the
fibrillar (or protofibrillar) oligomers.
ECD. In order to gain information on the conformation of the
oligomers formed, ECD curve was analysed, and a mixture of b-
sheet and disordered structures were found (Figure 9A). These
indicate the protofibrillar fibrillar nature of these oligomers.
TEM. The TEM measurements (Figure 8) revealed the size of
the globular oligomers in their dehydrated and stained state. The
oligomers were observed to be spherical with an average diameter
of 7.463.3 nm. Detailed analysis of the sizes demonstrated the
presence of two size classes: the smaller oligomers possessed an
average size of 4.961.0 nm (dmin = 2.8 nm, dmax = 6.9 nm), and
the larger ones a size of 10.462.4 nm. Again, the presence of two
Figure 6. ELISA results. (A) Effects of multivalency on the affinities. Normalized absorbances recorded in capture ELISA experiments, where the
biotinyl-7 (circles), -8 (triangles) or -1 (squares) are attached to the streptavidin functionalized plate and the increasing surface concentration of Ab is
observed through the BAM10 antibody. Fitted curves are given (dashed), IC50 values are 126 nM, 933 nM and 12 mM for biotinyl-7, -8 and -1,
respectively. (B) ELISA curves measured for biotinyl-7 (circles), -9 (triangles) and -10 (squares) with oligomeric Ab and the IC50 values are 126 nM,
4.4 mM and 18.5 mM, respectively. (C) ELISA curves recorded for oligomeric Ab (circles) and fibrillar Ab (squares) with biotinyl-7, the IC50 values are
126 nM and 886.2 nM, respectively.
doi:10.1371/journal.pone.0039485.g006
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oligomer populations could be assumed. Monomers could not be
observed in the TEM images.
DLS. Dynamic light scattering (DLS, Figure S6) measure-
ments furnished a size distribution curve of the oligomers, where
the frequencies of the different sizes were normalized to the
intrinsic volume of the scattering particles. The primary frequency
data provided by the DLS measurements were somewhat
distorted, as the contribution of a scattering particle to the total
measured intensity of the scattered light is directly proportional to
the sixth power of its size. Normalization of the frequencies to the
intrinsic volume therefore provides a distribution with less
distortion. This method can be applied only when the scattering
particles are spherical; the TEM images proved the spherical
nature of the Ab(1–42) oligomers. The DLS data reflected
a bimodal size distribution curve, demonstrating that the oligomer
population was heterogeneous. The maximal values (10.1 nm and
37.8 nm) were relatively large, but it should be considered that the
measured values were hydrodynamic diameters, for the fully
hydrated state of the peptide assemblies, together with the solvent
shell of the particle. The ratio of the frequencies of the two size
classes was , 4:1, indicating, that the small oligomers were
overrepresented as compared with the large assemblies. Notewor-
thy is that the presence of large scattering particles could suppress
the contribution of the small ones to the total intensity, which
caused an artifact: monomers can not be observed if large
oligomers are present in the sample.
NMR. 1H-NMR spectra (Figure S7) were recorded for the
starting Ser26 depsipeptide iso-Ab(1–42) at pH 3 and after
buffering the medium to pH 7.4. iso-Ab(1–42) at acidic pH
exhibits narrow peaks, indicating that it exists mostly in
monomeric form. On switching to the native sequence through
setting of the physiological pH, the total peak intensity dropped to
30%, as oligomer species with MW . ,100 kDa (d.,3–4 nm)
were outside the detection limit of the solution phase 1H-NMR for
T2 relaxation reasons. The narrow peaks can be assigned to the
Figure 7. Selective binding to the LMW Ab oligomers in the nM range. Size exclusion chromatographic separation of the HMW and LMW
fractions of the Ab oligomeric sample (top panel). Concentration-dependent dot blot experiments performed with the HMW (A) and the LMW
fractions (B). The ligand loadings were 10 mg aliquots of 7, and the sequence specific antibody BAM10 (1:500) was utilized. Lanes within the panels
are parallel experiments.
doi:10.1371/journal.pone.0039485.g007
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residual monomeric and possibly LMW oligomeric (N,4)
fractions.
Foldamer synthesis
Foldamers were synthesized on solid support with standard
Fmoc-chemistry. Foldamers and biotinyl-1 were synthesized on
a Tentagel R RAM resin (0.17 mmol g21) on a 0.1 mmol scale
with 1-[bis(dimethylamino)methyliumyl]-1H-1,2,3-triazolo [4,5-
b]pyridine-3-oxide (HATU) as coupling reagent. The octapeptide
(Gly)7 Cys-amide was synthesized by conventional Fmoc-based
SPPS on Rink-amide resin, applying DCC/HOBt activation. The
amino acid incorporation was monitored by means of the Kaiser
test and by the cleavage of aliquots from the resin. The peptide
sequences were cleaved from the resin with cocktail of TFA/H2O/
DTT/TIS (90:5:2.5:2.5) at room temperature for 3 h. The TFA
was removed in vacuo, and the peptide was precipitated in dried
diethyl ether. The resulting free peptide precipitate was filtered off,
were dissolved in 10% aqueous acetic acid, and lyophilized. The
crude peptide was purified by RP-HPLC on a Phenomenex Luna
10 m column (10 mm x 250 mm). The solvent system consisted of
0.1% TFA in water (A), and 0.1% TFA in 80% acetonitrile (B); the
default gradient was 0% – 40% B during 15 min, and then 40% –
70% during 60 min at a flow rate of 4 mL min21, with detection
at 206 nm. The gradient was customized where necessary.
Figure 8. Affinity precipitation as detected by TEM. (A) TEM image of the 72 mM Ab oligomer. (B) TEM image of the 72 mM Ab oligomer upon
addition of 36 mM 7.
doi:10.1371/journal.pone.0039485.g008
Figure 9. No change was observed in the Ab secondary structure. (A) Observed ellipticities in ECD for 36 mM Ab oligomer (thick black), 9 mM
7 (thin black), and 36 mM Ab +9 mM 7 (thick dashed). The hypothetical sum of the ECD curves of the pure samples (thin dashed). (B) ThT binding
experiment carried out on 36 mM oligomeric Ab (white bars) and on 36 mM oligomeric Ab +7 1:1 mixtures. The relative fluorescence values were
monitored up to 24 h.
doi:10.1371/journal.pone.0039485.g009
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Synthesis of the tetra-maleimidopropionyl-PAMAM
conjugate
300 ml 25 wt% methanol solution of polyamidoamine dendri-
mer generation 0, ethylenediamine core (0.4 mmol, Sigma
Aldrich) was lyophilized for 1 h to remove methanol. The
resulting oily substance was dissolved in 1 ml DMF and added
dropwise to a mixture of 1.2 mmol maleimidopropionic acid,
248 mg DCC and 163 mg HOAt dissolved in DMF. The mixture
was stirred for 4 h at ambient temperature, diluted with water and
lyophilized to dryness. Prior to purification, the white powder was
dissolved in a mixture of ACN (80%)/TFA (0.1%)/H2O,
sonicated for 10 min, diluted with 0.1% TFA/H2O solution,
filtered through a glass filter and injected onto a Phenomenex
Luna C18 (250610 mm, 100 A˚, 5 mm) semipreparative HPLC
column, applying ACN (5–50%)/TFA (0.1%)/H2O gradient
elution at 3.0 ml min21 flow rate. ESI-MS spectrum: [MH+]:
1121.69; [MH2
2+]: 561.43 (calculated MW: 1121.3) For charac-
terization of the materials see Figures S7, S8, S9, S10, S11.
Synthesis of 7-11 and biotinyl-7-11
4 mmol (20.0 mg) N,N,N,N-tetra-maleimidopropionyl-PA-
MAM(G0) was dissolved in 8 ml 50 mM NaH2PO4/Na2HPO4
buffer (pH = 7.1). 19.2 mmol peptide (1-Gly-Gly-Cys, biotinyl-1-
Gly-Gly-Cys or (Gly)7Cys-amide) was dissolved in 1 ml of the
same solution, and added dropwise to the dendrimer under
constant stirring. The reaction was stirred for 4 h at ambient
temperature, then deep-frozen and left to stand overnight at
220uC. The following day, the mixture was injected directly onto
a Phenomenex Jupiter C4 (250 x 10 mm, 300 A˚, 10 mm)
semipreparative HPLC column and purified by ACN (0–70%)/
TFA (0.1%)/H2O gradient elution at 3.0 ml min
21 flow rate. The
material content of the lyophilized 7, determined by thermo-
gravimetry, was 95%.
Compound 8 was synthesized the same way, but bis-maleimido-
butane linker was utilized for the ligation.
Transmission electron microscopy
Oligomer solution was placed on formvar-carbon-coated 400-
mesh copper grids (Electron Microscopy Sciences, Washington,
PA) and stained negatively with uranyl acetate. The aggregates
were characterized by TEM on a Philips CM 10 transmission
electron microscope (FEI Company, Hillsboro, Oregon, USA)
operating at 100 kV. Images were taken with a Megaview II Soft
Imaging System, routinely at magnifications of 646000 and
664000, and analyzed with an AnalySisH 3.2 software package
(Soft Imaging System GmbH, Mu¨nster, Germany).
Dynamic light scattering (DLS)
For DLS measurements, 500 mL Ab(1–42) solution (c = 72 mM)
was prepared in PBS, and placed in a low–volume sizing cell. Size
distribution was measured at 25uC on a Malvern Zetasizer Nano
ZS Instrument (Malvern Instruments Ltd. Worcestershire, UK)
equipped with a He-Ne laser (633 nm) by means of Non-Invasive
Back Scatter (NIBSH) technology, which involves detection of the
scattered light at an angle of 173u. A titration routine was
formulated consisting of 12 independent measurements with a 2-
min delay after each. The calculated amount of 7 solution was
added to the Ab after every second measurement. During the
Figure 10. Lower tendency of the LMW Ab oligomer fraction to affinity precipitation. (A) SEC analysis of pure Ab oligomers (black) and
mixtures of 50 mM Ab oligomers with 7 in 0.25 (green) and 1.0 (blue) equivalents. The samples were injected on the SEC column after filtration. The
control SEC chromatogram of 7 was recorded (red) and it exhibited anomalously longer retention time due to its compact geometrical arrangement.
(B) LC-MS results on the LMW fraction taken at 19 min. Both Ab and 7 were identified in the chromatogram in a comparable amount. (C) LC-MS
results on the HMW precipitate, which confirmed the heterocomplex nature of the product.
doi:10.1371/journal.pone.0039485.g010
Figure 11. Ab oligomers did not precipitate out of the solution
at 1 mM. Ab concentrations determined by ELISA in supernatants
obtained from samples containing 1 mM Ab oligomer mixed with 0, 0.2,
0.5 and 1.0 equivalents of 7 and centrifuged at 150006g (room
temperature, 3 h).
doi:10.1371/journal.pone.0039485.g011
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titration, the molar quantity of 7 varied between 0–35 mM. For
a single measurement, the correlation function and distribution of
the apparent hydrodynamic diameter (dh) over the scattered
intensity of the particles were determined on the basis of 14 scans.
The translational diffusion coefficients were obtained from the
measured autocorrelation functions by using a fitting algorithm
incorporated in the software package Dispersion Technology
Software 5.1 (Malvern Instruments Ltd. Worcestershire, UK).
NMR spectroscopy
NMR spectra were recorded on a 600 MHz Bruker Avance
spectrometer equipped with a 2.5 mm triple-resonance capillary
probe. The protein and the ligands were dissolved in 20 mM,
pH 7.4 phosphate buffer (90% H2O, 10% D2O) containing 0.02%
NaN3. Spectra were acquired with the WATERGATE solvent
suppression pulse scheme. For the STD and tr-NOE measure-
ments, the Ab(1–42) and the ligand concentrations were 100 mM
and 2.0 mM, respectively. As a reference, STD and tr-NOE
experiments were also performed without the target, containing
the ligand alone.
STD spectra were acquired by using a series of 40 equally
spaced 50-ms Gaussian-shaped pulses for selective saturation of
the protein, with a total saturation time of 2 s. The frequency of
the on-resonance saturation was set at 21 ppm and the off-
resonance saturation frequency was set at 40.0 ppm. A total of 2 k
scans were collected for each pseudo 2D experiment. The 2D tr-
NOESY measurements were performed with 128 increments and
256 scans, with a NOE mixing time of 200 ms.
Signal assignments were performed by using the 2D TOCSY
and ROESY spectra of the 2 mM samples recorded at 298 K in
Figure 12. Ligand 7 protects against Ab-induced LTP impairment. (A) The oligomeric Ab(1–42) sample applied at 720 nM hinders synaptic
potentiation. (B) Compound 7 applied at 950 nM prevents the LTP impairment caused by Ab(1–42) oligomers. The control substance 11 has no
effect against Ab(1–42) oligomers. (C) Neither 7 nor 11 alone exerted any effect on LTP in the absence of Ab oligomers. (D) The summarized results
observed 180 min after LTP (**P,0.01, ***P,0.001 versus control). Statistical analysis was carried out by using two-tailed Student’s t-test, n = 6 or 7
slices per group. Data are presented as means 6SEM. (E) Divalent 8 applied at 950 nM did not exhibit statistically significant effect against Ab(1–42)
oligomers. Arrows indicate LTP induction, EPSP stands for excitatory postsynaptic potential.
doi:10.1371/journal.pone.0039485.g012
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aqueous buffer and d3-MeOH. Because of the better signal
resolution at lower temperatures, the spectra of 7 in buffer were
acquired at 280 K. ROESY measurements were carried out with
a mixing time of 400 ms and with 32 and 64 scans. TOCSY
measurements were acquired with homonuclear Hartman–Hahn
transfer with the MLEV17 sequence, with a mixing time of 80 ms;
the number of scans was 32. For all the 2D spectra, 2048 time
domain points were applied, while the number of increments was
128 and 512 for 1 and 7, respectively. The processing was carried
out by using a cosine-bell window function, with single zero filling
and automatic baseline correction.
Molecular mechanics and NMR structure refinement
Molecular mechanical simulations were carried out in the
Molecular Operating Environment (MOE) of the Chemical
Computing Group. For the energy calculations, the MMFF94x
force field was used, without a cut-off for van der Waals and
Coulomb interactions. The implicit water model of GB/VI
(Generalized Born) was applied. The conformational sampling
was carried out by using the hybrid MC/MD simulation (as
implemented in MOE) at 300 K with a random MC sampling step
after every 10 MD steps. The MC-MD was run with a step size of
2 fs for 20 ns, and the conformations were saved after every 1000
MD steps, which resulted in 10000 structures. For the NMR-
restrained simulation, the upper distance limits were calculated by
using the isolated spin-pair approximation and classified by
following the standard method (strong: 2.5 A˚, medium: 3.5 A˚,
and weak: 5.0 A˚). The lower limit was set at 1.8 A˚. Restraints were
applied as a flat-bottomed quadratic penalty term with a force
constant of 5 kcal A˚22. The final conformations were minimized
to a gradient of 0.05 kcal mol21 A˚21) and the minimization was
applied in a cascade manner, using the steepest-descent, conjugate
gradient and truncated Newton algorithm.
Isothermal titration calorimetry
Isothermal titrations were performed with a Microcal VP-ITC
microcalorimeter. The binding experiments were performed in
PBS pH 7.4. The buffer solution was degassed. The concentra-
tions of the ligands and Ab were corrected for the material
content. In individual titrations, 10 mL of ligand was injected from
the computer-controlled 300-mL microsyringe at intervals of 300 s
into the Ab oligomer solution dissolved in the same buffer as the
ligand. The microsyringe stirring was set to 295 rpm. All
measurements were made at 288 K. The Ab concentrations in
the cell were either 72 mM or 36 mM, and the concentrations of 7
were 175 mM and 222 mM respectively. The total ligand
concentration was set in the syringe so that the titration stopped
when the precipitation became excessive. Control experiments
were performed by injecting the ligand into a cell containing buffer
with no target, and the heats of dilution were subtracted from
those measured in the presence of Ab. Titrations were also
performed with buffer in the syringe and Ab oligomer sample in
the cell to check for the heat response of Ab dilution itself. The
dilution heat of the Ab oligomer samples was constant and
negligible. Since the target is inherently inhomogeneous, and an
a priori model of the binding events is not available,. the
experimental data were fitted to the two independent site binding
model by using a nonlinear least-squares procedure, with DHb,
DHb’, Ka, Ka’ (association constants), N and N’ (number of
binding sites for monomer), as adjustable parameters. The
exothermic peaks appearing after the fully precipitated phase
was reached, were omitted from the regression. The results are
summarized in Table S1.
Electronic circular dichroism
CD spectra were measured on a Jasco J815 dichrograph in
a 1.00 cm cell using PBS (pH = 7.4) as solvent. Three spectra were
accumulated for each sample. The baseline spectrum recorded
with only the solvent and it was subtracted from the raw data.
ELISA
An indirect ELISA experiment was conducted on 96-well
streptavidin-coated clear plates (Pierce, Cat.No. 15500, Rockford,
IL, US). Biotinyl-compounds bound to streptavidin by incubating
1 mg substance per well for 2 h at ambient temperature. Ab(1–42)
was dissolved in PBS to 100 mM and incubated for 24 h at 37uC.
Serial dilutions of the incubated peptide were prepared, and
supplemented with Tween (0.05% v/v of the final volume) and
BSA (1% w/v of the final volume) prior to use. Compounds were
incubated with Ab oligomers for 1 h at ambient temperature.
Bound Ab was detected by monoclonal anti-Ab AB clone Bam-10
(Sigma-Aldrich) applied in 1:10000 dilution for 1 h followed by an
incubation with anti-mouse IgG-HRP (DakoCytomation,
Glostrup Denmark). Finally, 100 mL tetramethylbenzidine
(TMB) solution (Cell Signaling Tecnology Inc., Danvers, USA)
was introduced into the wells, and the change in the absorbance at
370 nm was monitored constantly, without the addition of stop
solution, on a 96-well plate reader (NOVOstar OPTIMA, BMG
Labtech, Offenburg, Germany) equipped with a xenon lamp,
fiberglass optics and a shaking microplate carrier. Abs370 values
were read near complete saturation of the signal intensity, which
was observed after 40 min. For the quantitative analysis of the
results, nonlinear regressions were carried out and the IC50 values
were optimized with fixed number of blocked ligands per Ab
peptide as determined by ITC [80]. For 7, the iteration converged
to IC50 = 126 nM (N = 0.25), and marked deviations from the
experimental curve were found indicating a substoichiometric
higher affinity binding. For 8 and 1, the IC50 values were 933 nM
(N = 0.5) and 12 mM (N = 1.0). Concerning the steric shielding
exerted by the solid support, the apparent binding parameters
estimated from ELISA are in good accordance. Measurements
with fibrillar Ab and 7, revealed an affinity similar to the value
obtained for the oligomeric Ab – 8 interaction, which may suggest
that tetravalent 7 can attach to the fibrillar Ab only as a divalent
ligand.
Size Exclusion Chromatography
iso-Ab(1–42) was dissolved in sodium hydrocarbonate buffered
saline (pH 7.4) to 50 mM and incubated for 24 h at 37uC. The
oligomeric Ab was loaded onto an A¨kta Purifier FPLC system (GE
Healthcare, UK) equipped with a Superose 6 10 300 column.
Sample was eluted at a flow rate of 0.5 ml/min. FPLC chromato-
gram was taken at 280 nm and 1 ml fractions were collected
during the separation. Fractions corresponding to the chromato-
graphic peaks (No.10–12 for peak a and 16–18 for peak b) were
pooled and their peptide content was equalized with running
buffer according to their concentration determined by UV
measurement at 220 nm.
SDS-PAGE and Western Blot
10-mL aliquots of the Ab oligomer samples were loaded onto
a 15% SDS-polyacrylamide gel without boiling prior to loading,
while 5 mL Kaleidoscope Precision Plus Protein TM (Bio-Rad
Laboratories, Ca, USA) standard was applied as MW marker.
After running, the gel was transferred to a nitrocellulose mem-
brane using an electroblotting apparatus (Bio-Rad Laboratories,
CA, USA). The membrane was blocked in TBS, 0.1% Tween-20
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(TBST), 5% non-fat dry milk and incubated overnight with
primary antibody (1:1000 OC (Millipore) or 1:2500 Bam-10
(Sigma) at 4uC. The following day the membranes were incubated
with an anti-mouse-HRP secondary antibody (1:10000; DakoCy-
tomation, Glostrup, Denmark) and Pierce ECL Western Blotting
Substrate (PIERCE, Rockford, IL). Blots were exposed to Kodak
film (Sigma).
Dot Blot experiment: binding study
10 mg aliquots of 7 dissolved in TBS were spotted onto a 0.1 mm
nitrocellulose membrane with a Dot Blot apparatus (Bio-Rad
Laboratories, Ca, USA). The spots were washed in the instrument
with 26200 ml TBS. After serial dilutions of both oligomer
fractions a and b, 100 ml aliquots were loaded in the wells and
incubated with gentle shaking for 1 h at RT. The membrane was
washed twice with TBS, blocked with a blocking solution (5%
BSA, 0.1% Tween-20 in TBS, 2630 min) and incubated with the
sequence-specific Bam-10 (Sigma) antibody in 1:500 dilution
overnight at 4uC. After washing of the membrane twice with
blocking solution, the secondary antibody (HRP-conjugated anti-
mouse AB; Dako Cytomation, Glostrup, Denmark) was incubated
with the membrane in 1:10000 dilution (2 h at 4uC) followed by
washing twice with blocking solution and twice with 0.1% Tween-
20 in TBS. 8. The membrane was incubated in ECL Western
Blotting Substrate (Pierce) for 1 min and exposed to Kodak film
(Sigma).
ThT binding measurements
ThT (Sigma-Aldrich) was dissolved in 50 mM NaH2PO4/
Na2HPO4 buffer (pH = 7.0) to a final concentration of 25 mM.
This working solution was kept at 4 uC protected from light and
used during the measurement. Two identical 50 mM Ab oligomer
samples were prepared and one of them was mixed with 7 to a final
concentration of 50 mM, and the ThT signal intensity was
monitored up to further 24 h. At each time point, samples were
carefully vortexed to get a homogeneous sample and to resuspend
the precipitated material, and 50 mL aliquots were mixed with
500 mL of working solution. ThT-peptide mixtures were vortexed
again and 150 mL aliquots were placed on a 96 well plate. ThT
fluorescence was measured on a plate reader at lex = m and
lem = 480 nm. Data mean values and S.D. were calculated from
three parallel measurements.
Sample preparation and ELISA for concentration
determination of Ab in the precipitation study
1 mM solution of the Ab oligomer sample was prepared. This
solution was divided to 4615 ml fractions and 7 was added to
three samples in 1, 0.5 or 0.2 mM final concentration, respectively.
All the four samples were divided into three fractions (265 ml).
One fraction from each sample was centrifuged at 150006g at RT
for 3 hours in a Roth MIKRO 200 Microcentrifuge (Carl-Roth
GmbH Karlsruhe, Germany) centrifuge. One fraction from each
sample was let undisturbed at RT in the meantime. After the
centrifugation 361 ml supernatant was removed from each
fraction and subjected with the unseparated ones to concentration
determination by ELISA.
Different amounts of Ab (0.0001, 0.0003, 0.001, 0.003, 0.01,
0.03, 0.1, 0.3 mg pro well) were coated in the wells (6 parallels for
each concentration) of a 96 well plate. The supernatant of the
centrifuged samples was diluted two times and 10–10 ml was
added to the empty wells. The plate was incubated for 20 h at
4uC, using a coating solution (15 mM Na2CO3, 35 mM
NaHCO3, 3 mM NaN3). The wells were then blocked using
a blocking solution (10 mM NaHCO3, 0.45% NaCl, 0.1% Tween-
20, 1% BSA) at room temperature. After blocking, the plate was
washed three times with a washing buffer (10 mM NaHCO3,
0.45% NaCl, 0.1% Tween- 20). A monoclonal Ab antibody
(BAM10, SIGMA) was added to the wells in blocking solution for
1 h at room temperature. After washing twice, the wells were
incubated with HRP-conjugated anti-mouse secondary antibody
(Dako Cytomation, Denmark, Glostrup) in blocking solution. The
plate was washed two times, and TMB reagent (Cell Signaling
Technology) was added to the wells. Without using a stopping
reagent, the absorbance at 370 nm was constantly monitored
using a FLUOstar OPTIMA Multidetection Microplate Reader
(BMG LABTECH, Offenburg, Germany). Data values were read
at the saturation point of the signal curves. The supernatants were
analysed according to the concentration calibration.
Hippocampal slice electrophysiology
Via standard procedures, 350-mm-thick transverse hippocampal
slices were prepared from the brain of 7-months-old mice (CD1,
Animal Breeding Facility, University of Szeged) with a McIlwain
tissue chopper (Campden Instruments, Loughborough, UK).
Slices were incubated in standard artificial cerebrospinal fluid
(ACSF) at ambient temperature for 60 min, during constant
gassing with 95% O2–5% CO2. The ACSF contained (mM):
NaCl, 130; KCl, 3.5; CaCl2, 2; MgCl2, 2; NaH2PO4, 0.96;
NaHCO3, 24; and D-glucose, 10 (pH 7.4). Individual slices were
transferred to a 3D-MEA chip with 60 tip-shaped and 60-mm-high
electrodes spaced at 100 mm (Ayanda Biosystems, S.A., Lausanne,
Switzerland). The slice was continuously perfused with oxygenated
ACSF (1.5 ml min21 at 34 uC) containing 720 nM Ab(1–42)
oligomers and/or 950 nM ligand throughout the recording
session. Data were recorded with a standard, commercially
available MEA setup (Multi Channel Systems MCS GmbH,
Reutlingen, Germany). The Schaffer-collateral was stimulated by
injecting a biphasic current waveform (2100/+100 ms) through
one selected electrode at 0.033 Hz. Care was taken to choose the
stimulating electrode in the same region from one slice to the
other. The peak-to-peak amplitudes of fEPSPs at the stratum
pyramidale and stratum radiatum of CA1 were analyzed. After
a 30-min incubation period, the threshold and the maximum of
stimulation intensity for evoke responses was determined. To
evoke responses, 30% of the maximal stimulation intensity was
used. LTP was induced by applying a theta-burst stimulation
(TBS) pattern at the maximal stimulation intensity. The TBS
comprised four trains administered at 20-s intervals with 10 bursts
given at 5 Hz per train and 4 pulses at 100 Hz per burst.
Statistical analysis was carried out by using two-tailed Student’s t-
test. For representative raw data see Figure S12.
Supporting Information
Figure S1 TOCSY spectrum (A) and ROESY spectrum
(B) of 1. NMR-derived conformation of 1: H14 helix (C).
tr-NOESY recorded on the mixture of 1 and the Ab(1–42)
oligomers and the NOE crosspeaks supporting the H14 helical
binding conformation (D).
(TIF)
Figure S2 Constitutions of 7 and 8.
(TIF)
Figure S3 Representative raw ITC data obtained with
the 72 mM Ab(1–42) oligomer in the titration cell and
175 mM 7 in the syringe. The curve was corrected for the heat
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of dilution of the ligand, and polynomial baseline correction was
applied.
(TIF)
Figure S4 ITC enthalpograms for the titration of the
72 mM Ab oligomer with 9 (A), 10 (B) and 11 (C). Fitting of
the titration curves revealed weak (KD.2 mM) and substoichio-
metric interactions for both 9 and 10. This indicated that these
changes in the recognition segments lead to the loss of tight and
specific binding. For 11, the curve fitting did not converge,
because the exothermic heat response (negative DH values) with
negative slope cannot be associated with a binding equilibrium.
(TIF)
Figure S5 SDS-PAGE and Western Blot characterization
of the Ab oligomer sample. The results on the left (BAM10)
and the right (OC) panels were obtained on identical samples. The
incubation time was measured from dissolving iso-Ab in the
pH 7.4 buffer. The monomeric fraction is not stained by OC,
whereas BAM10 has a limited efficiency in staining the LMW
oligomers. The OC staining revealed that the monomeric
population can be minimized with the incubation time and after
24 h a mixture of LMW and HMW oligomers was obtained.
(TIF)
Figure S6 (A) DLS measurement: hydrodynamic diameter
distribution of the Ab oligomers in PBS, c = 72 mM, after
incubation for 24 h. Frequencies are normalized to the intrinsic
volume of the scattering particles. (B) TEM image of the oligomers
on formvar-carbon coated grids, stained with uranyl acetate,
visualized at 920006magnification.
(TIF)
Figure S7 1H-NMR spectra recorded for the Ser26
depsipeptide iso-Ab(1–42) at pH 3 (A) and after buffering
of the medium to pH 7.4 for the same sample (B). The
intensities are corrected for the small dilution.
(TIF)
Figure S8 Purity and integrity of 7, 11 and biotinyl-7.
Analytical HPLC chromatograms of the purified 7, 11 and
biotinyl–7 are given in panels (A), (B) and (C), respectively.
Conditions: solution A: 0.1% TFA in water; B: 80% ACN, 0.1%
TFA in water Applied gradients: 7: 0–20% B in 20 min; 7: 40–
64% B in 12 min, biotinyl-7: 25–75% B in 25 min Column
Phenomenex Luna 5 C18 column 1.2 ml/min flow rate at
ambient temperature.
(TIF)
Figure S9 Purity and integrity of 7, 11 and biotnyl-7.
ESI-MS spectra of the purified 7, 11 and biotinyl-7 are
given in panels (A), (B) and (C), respectively.
(TIF)
Figure S10 1H-NMR WATERGATE spectra recorded in
H2O:D2O 90:10 (buffer pH 7.4) for 7 (A) and 11 (B). The
signal broadening in the amide region is due to the chemical
exchange with solvent protons. Signal broadening in methanol was
not observed. Inset displays spectrum of 7 in d3-MeOH.
(TIF)
Figure S11 1H-NMR WATERGATE spectra for 7–11 (A–
E, respectively) recorded in H2O:D2O 90:10 (phosphate
buffer pH 7.4).
(TIF)
Figure S12 Superimposed raw data before (black) and
180 min after (red) LTP induction (A), untreated; (B),
Ab(1–42) oligomer; (C), Ab(1–42) oligomer +7; (D), Ab(1–
42) oligomer +11).
(TIF)
Table S1 Affinities to Ab oligomers determined for 1, 7,
8, 9 and 10 with ITC and ELISA.
(DOC)
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